ECM
ACRS icon

Endurant Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Endurant Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-376,200
Closed -$94K – 53
2019
Q4 		$94K Buy
+376,200
New +$623K 0.03% 53

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Endurant Capital Management's ACRS Position: Q1 2024 in Review

Endurant Capital Management sold out of Aclaris Therapeutics (ACRS) in Q1 2024, closing a stake of 148,400 shares — an estimated $156K sold.

Endurant Capital Management first reported a position in ACRS in Q1 2019 and held it in 13 quarters. The position peaked at $11.5M in Q1 2021. 98 funds tracked by Wall St. Rank hold ACRS as of Q1 2024.

  • Endurant Capital Management reported no remaining Aclaris Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Endurant Capital Management sold 148,400 Aclaris Therapeutics shares in Q1 2024, an estimated $156K.
  • Endurant Capital Management first reported a position in Aclaris Therapeutics in Q1 2019 and held it in 13 quarters.
  • Endurant Capital Management's Aclaris Therapeutics position peaked at $11.5M in Q1 2021.
  • 98 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2024.

Based on Endurant Capital Management's 13F filing for Q1 2024.